OncRef

Clinical Trial: NCT02231749

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Bristol-Myers Squibb
Information Provided By:Bristol-Myers Squibb
Last Update Posted:2026-05-27

Study Overview

Brief Summary

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

Official Title

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Conditions

Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma

Intervention / Treatment

  • Biological: Nivolumab
  • Biological: Ipilimumab
  • Drug: Sunitinib

Other Study ID Numbers

  • CA209-214
  • 2014-001750-42
  • 2014

Start Date (Actual)

2014-10-16

Primary Completion Date (Actual)

2017-06-26

Study Completion Date (Actual)

2025-03-21

Enrollment (Actual)

1096

Study Type

Interventional

Phase

Phase 3